Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.

导出原文传递

翻译打印收藏纠错

第一作者： Kanerva,Lahdensuo

第一单位： Department of Urology, Meilahti Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

作者： Kanerva,Lahdensuo ^[1] ; Andrew,Erickson ^[2] ; Irena,Saarinen ^[3] ; Heikki,Seikkula ^[4] ; Johan,Lundin ^[2] ; Mikael,Lundin ^[2] ; Stig,Nordling ^[5] ; Anna,Bützow ^[6] ; Hanna,Vasarainen ^[1] ; Peter J,Boström ^[4] ; Pekka,Taimen ^[3] ; Antti,Rannikko ^[1] ; Tuomas,Mirtti ^[7]

作者单位： Department of Urology, Meilahti Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. ^[1] Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland. ^[2] Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland. ^[3] Department of Urology, University of Turku and Turku University Hospital, Turku, Finland. ^[4] Department of Pathology, HUSLAB and Medicum, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. ^[5] United Medix Laboratories, Pathology, Helsinki, Finland. ^[6] Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland.;Department of Pathology, HUSLAB and Medicum, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. ^[7]